Pharming
Pharming is a company.
Active
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at Pharming.
Pharming is a company.
Key people at Pharming.
Key people at Pharming.
Pharming Group N.V. is a global biopharmaceutical company focused on developing and commercializing protein replacement therapies and precision medicines for rare diseases, primarily hereditary angioedema (HAE) and other rare immunological disorders. Its lead products include RUCONEST, a recombinant C1 esterase inhibitor for acute HAE attacks, and Joenja (leniolisib), an oral PI3Kδ inhibitor for activated phosphoinositide 3-kinase delta syndrome (APDS). Pharming serves patients worldwide across more than 30 markets, addressing unmet medical needs in rare, debilitating, and life-threatening diseases, with ongoing development programs including gene therapy candidates like OTL-105. The company has shown growth momentum through strategic collaborations with Novartis and Orchard Therapeutics and expanding its product pipeline[1][2][3].
Founded in 1988 and headquartered in Leiden, the Netherlands, Pharming was established to pioneer treatments for rare diseases. Its leadership, including CEO Fabrice Chouraqui (MBA, PharmD), has steered the company through evolving focus areas from protein replacement therapies to precision medicines and gene therapies. Early traction came from RUCONEST’s approval and commercialization, which validated Pharming’s approach to rare disease treatment and enabled further innovation and partnerships[1][2].
Pharming rides the growing trend of precision medicine and gene therapy targeting rare diseases, a sector gaining momentum due to advances in biotechnology and regulatory incentives for orphan drugs. The timing is favorable as healthcare systems increasingly prioritize treatments for rare conditions with high unmet needs. Market forces such as rising patient advocacy, improved diagnostic capabilities, and expanding global rare disease awareness support Pharming’s growth. Its innovations contribute to the broader ecosystem by advancing therapeutic options and setting benchmarks for safety, efficacy, and patient-centric care in rare disease treatment[1][2].
Pharming is poised to expand its influence through upcoming clinical readouts and label expansions for Joenja, geographic market growth, and potential commercialization of gene therapy candidates like OTL-105. Trends shaping its journey include the maturation of gene therapy technologies, increasing adoption of precision medicines, and evolving regulatory landscapes favoring rare disease innovation. Pharming’s continued strategic collaborations and pipeline diversification suggest a trajectory toward becoming a leader in rare disease therapeutics, with growing impact on patient outcomes and the biotech industry at large[2][3].
